Loading
A phase 1/2 trial of IOV-3001 in melanoma and uveal melanoma, run by Iovance Biotherapeutics, Inc., now recruiting.
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel is a phase 1/2 interventional study registered as NCT06940739 by Iovance Biotherapeutics, Inc., with 42 participants planned, started 2025-03-11 and due to reach its primary completion in 2032-06. Interventions recorded: IOV-3001.
Shares Iovance Biotherapeutics, Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Iovance Biotherapeutics and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.